G1 Therapeutics (GTHX)
(Delayed Data from NSDQ)
$7.09 USD
0.00 (0.00%)
Updated Aug 9, 2024 04:00 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
G1 Therapeutics [GTHX]
Reports for Purchase
Showing records 321 - 340 ( 357 total )
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
G1 Therapeutics Announces Positive Phase 2 Trilaciclib Myelopreservation Data in First-Line SCLC Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Trila Triple Combo Data Positive, Looking Forward to TNBC Data at SABCS
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
G1 Therapeutics to Present Phase 2 Trilaciclib Data at San Antonio Breast Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
3Q Financials; Data-Rich Q4 to Set up 2019 Regulatory Guidance
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
G1 Therapeutics 3Q18 Results; Several Milestones Coming Before Year-End
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Biotechnology - ESMO 2018 Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Small Cell Update Confirms Multi-Lineage Preservation, Trend to PFS Improvement
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
G1 Therapeutics Presents Positive Phase 2 Trilaciclib Data in SCLC at ESMO; PT Adjusted
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Biotechnology -ESMO 2018 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
G1 Therapeutics to Present Posters at ESMO on Trilaciclib in First-line SCLC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Protocol Amendment to Ph 2 Trila Triple Combo Study Could Add to Filing
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Unclassified
G1 Therapeutics Plans Expedited Analysis of Trilaciclib Phase 2 in SCLC; Raising Price Target to $79
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Unclassified
Therapeutics Takeaways, CDK4/6i Platform Progress
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Unclassified
Company: G1 Therapeutics
Industry: Unclassified
Positive Sentiment Going into Q4 Data Updates
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Unclassified
G1 Therapeutics 2Q18 Results and Pipeline Update
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Unclassified
Company: G1 Therapeutics
Industry: Unclassified
Company: G1 Therapeutics
Industry: Unclassified
Promising Preliminary G1T38 Phase 1b Data at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E